Intellia Therapeutics was formed to lead the industry in one of the most promising new areas of therapeutic development: gene editing and repair using CRISPR-Cas9 technology. Intellia holds exclusive access to one of the most comprehensive intellectual property platforms available for the therapeutic use of CRISPR-Cas9. The company is advancing a broad pipeline toward clinical development, including ex vivo and in vivo approaches. Intellia went public in May 2016 (NASDAQ: NTLA).
|Partners||Caribou Biosciences; Novartis; Regeneron|